Jakub Svoboda

Dr. Jakub Svoboda is an Associate Professor of Medicine in the Department of Hematology-Oncology at the Perelman School of Medicine, University of Pennsylvania. He practices clinically at the Abramson Cancer Center and Perelman Center for Advanced Medicine, specializing in lymphoma and Hodgkin lymphoma treatment with a focus on advanced immunotherapies. As a Penn Medicine provider, he maintains hospital privileges at the Hospital of the University of Pennsylvania and sees patients aged 18+.

Dr. Svoboda completed his medical training at Yale University followed by residency and fellowship at the Hospital of the University of Pennsylvania. His research program centers on developing novel cellular immunotherapies, particularly CAR T-cell therapy for relapsed/refractory lymphomas. Recent work focuses on enhancing CAR T efficacy after treatment failure, optimizing lymphodepletion protocols, and managing treatment-related toxicities through multicenter clinical trials.

His publication record demonstrates consistent high-impact output in journals like NEJM and Nature Medicine, with 2023-2025 studies addressing critical challenges in lymphoma immunotherapy. Dr. Svoboda collaborates extensively with Penn's cellular therapy pioneers including Carl June and Stephen Schuster, contributing to both basic science and clinical translation. The Abramson Cancer Center provides his primary research infrastructure, supporting clinical trials in cellular therapies and combination regimens.

Dr. Svoboda actively treats patients through Penn Medicine's network, accepting numerous insurance plans and maintaining a strong clinical reputation reflected in patient reviews highlighting his caring approach and communication skills. His work bridges cutting-edge research with direct patient care in hematologic malignancies.